Drugs / AdVEGF-D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01002430 | Jan 2010 → Jun 2015 | myocardial infarction | Kuopio University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdVEGF-D | “The phase I KAT301 trial investigated the use of intramyocardial adenoviral vascular endothelial growth factor-DΔNΔC (AdVEGF-D) gene therapy (GT) to alleviate symptoms in...” PMID 35750637 ↗ Jul 2022 |
| Known as | adenoviral vascular endothelial growth factor-DΔNΔC | “The phase I KAT301 trial investigated the use of intramyocardial adenoviral vascular endothelial growth factor-DΔNΔC (AdVEGF-D) gene therapy (GT) to alleviate symptoms in...” PMID 35750637 ↗ Jul 2022 |